FERD3L: A Potential Drug Target and Biomarker for Neurological Disorders
FERD3L: A Potential Drug Target and Biomarker for Neurological Disorders
FERD3L, also known as BHLHa31, is a protein that is expressed in the brain and is known for its role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the rest of the body and is designed to protect it from harmful substances. However, this barrier can also prevent the entry of many essential nutrients and medications. FERD3L plays a crucial role in breaking down this barrier and allowing necessary substances to enter the brain.
Research has suggested that FERD3L may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This is because FERD3L has been shown to be involved in the development and progression of these disorders. For example, studies have shown that mice that have been genetically modified to lack FERD3L have reduced anxiety-like behavior and are less likely to develop Alzheimer's disease.
In addition to its potential as a drug target, FERD3L has also been shown to be a potential biomarker for various neurological disorders. This is because the loss of FERD3L has been associated with the development of various neurological symptoms, including cognitive decline and motor impairments. For example, a study published in the journal Nature Medicine showed that individuals with Alzheimer's disease had lower levels of FERD3L in their brain compared to those without the disease.
The role of FERD3L in the regulation of the blood-brain barrier is also of interest as a potential therapeutic target. The blood-brain barrier is designed to keep harmful substances out of the brain, but it can also prevent the entry of essential nutrients and medications. FERD3L is involved in breaking down this barrier, allowing necessary substances to enter the brain. This suggests that FERD3L may be a useful target for treatments that aim to improve brain function or protect against neurological disorders.
In conclusion, FERD3L is a protein that is expressed in the brain and is known for its role in the regulation of the blood-brain barrier. The loss of FERD3L has been associated with the development of various neurological symptoms, and its role in breaking down this barrier has also been suggested as a potential therapeutic target. Further research is needed to fully understand the role of FERD3L in neurological and psychiatric disorders, as well as its potential as a drug target or biomarker.
Protein Name: Fer3 Like BHLH Transcription Factor
Functions: Transcription factor that binds to the E-box and functions as inhibitor of transcription. DNA binding requires dimerization with an E protein. Inhibits transcription activation by ASCL1/MASH1 by sequestering E proteins (By similarity)
The "FERD3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FERD3L comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1
